Stock CLPT CLEARPOINT NEURO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News ClearPoint Neuro, Inc.

Equities

CLPT

US18507C1036

Real-time Estimate Cboe BZX
Other stock markets
 18:06:19 03/05/2024 BST 		5-day change 1st Jan Change
5.78 USD +4.71% Intraday chart for ClearPoint Neuro, Inc. +9.89% -14.87%
04-30 Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory MT
04-29 ClearPoint Gets FDA Clearance For Neurosurgical Equipment MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
AQ
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PR
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory
MT
CLS partner ClearPoint Neuro receives FDA 510(k) clearance for Prism Bone Anchor Accessory enabling operating room placement of laser applicators
AQ
ClearPoint Gets FDA Clearance For Neurosurgical Equipment
MT
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
AQ
ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory
CI
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR Stereotactic System
AQ
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
AQ
ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR? Stereotactic System
CI
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
AQ
ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia
MT
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
GL
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PR
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency
AQ
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
AQ
Stifel Adjusts Price Target on ClearPoint Neuro to $9 From $8, Maintains Buy Rating
MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : ClearPoint Neuro, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Earnings Flash (CLPT) CLEARPOINT NEURO Posts Q4 Revenue $6.8M, vs. Street Est of $6.5M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLPT Stock
  4. News ClearPoint Neuro, Inc.